Dr. Sun serves as Vice President, Clinical Pharmacology and Translational Medicine at Cogent Biosciences with 20 years of experience in the biopharmaceutical industry. Before joining Cogent in December 2021, Dr. Sun served as Senior Director and Head of Clinical Pharmacology at Alkermes where she led Clinical Pharmacology support for multiple clinical programs in neuroscience and in immune-oncology. In today’s webinar, she will share her experience of utilizing model-based drug development approach such PBPK modeling to support the clinical development and FDA approval of LYBALVITM (OLZ/SAM) for the treatment of schizophrenia and bipolar I disorder. Earlier in her career, Dr. Sun held several roles of increasing responsibility in the area of Clinical Pharmacology, Translational Medicine and DMPK at Ziopharm Oncology, Alnylam and Wyeth/Pfizer. Dr. Sun received her Ph.D. in Chemistry & Chemical Biology and M.S. in Chemical & Biochemical Engineering from Rutgers University in New Brunswick, NJ and her B.S. in Material Sciences & Engineering from Tianjin University in China.
Lei Sun Vice President, Clinical Pharmacology and Translational Medicine Cogent Biosciences,